Related Experiment Video

Updated: Nov 9, 2025

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

15.1K

MicroRNA-30 regulates left ventricular hypertrophy in chronic kidney disease

Jingfu Bao1, Yinghui Lu1, Qinying She1

  • 1National Clinical Research Center of Kidney Diseases, and.

JCI Insight
|April 13, 2021
PubMed

Insights

Chronic kidney disease (CKD) causes left ventricular hypertrophy (LVH) by suppressing miRNA-30. Restoring miRNA-30 in heart cells can prevent or treat this condition, offering a new therapeutic target.

Area of Science:

  • Cardiovascular Biology
  • Nephrology
  • Molecular Biology

Background:

  • Left ventricular hypertrophy (LVH) is a major complication in chronic kidney disease (CKD).
  • MicroRNA-30 (miRNA-30) is a known regulator of LVH, but its role in CKD-induced LVH is unclear.

Purpose of the Study:

  • To investigate the role of miRNA-30 in the development of LVH in CKD.
  • To explore miRNA-30 as a potential therapeutic target for CKD-associated cardiovascular complications.

Main Methods:

  • Studied CKD rat models to assess LVH and myocardial miRNA-30 expression.
  • Utilized cardiomyocyte-specific miRNA-30 rescue and knockdown experiments in vivo and in vitro.
  • Investigated the effect of CKD-related factors on miRNA-30 and cardiomyocyte hypertrophy.

Main Results:

  • CKD induced LVH and suppressed myocardial miRNA-30 expression.
  • Restoring cardiomyocyte-specific miRNA-30 attenuated LVH in CKD rats.
  • miRNA-30 knockdown promoted cardiomyocyte hypertrophy via calcineurin signaling.
  • CKD-related factors suppressed miRNA-30, while miRNA-30 supplementation inhibited hypertrophy.

Conclusions:

  • CKD-induced LVH involves the suppression of cardiac miRNA-30.
  • miRNA-30 plays a protective role against cardiomyocyte hypertrophy in CKD.
  • miRNA-30 represents a novel therapeutic target for managing LVH in CKD patients.

Keywords:
CardiologyCardiovascular diseaseChronic kidney diseaseNephrology

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.3K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.0K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
650
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
145
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
160
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
128
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
255
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
588